XML 13 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 63,733 $ 59,074
Receivables from collaboration   23
Inventory 2,866  
Deferred costs from collaboration 22,742 13,539
Prepaid expenses and other current assets 1,423 4,018
Total current assets 90,764 76,654
Property and equipment - net 47,422 48,749
Other assets 1,248 1,009
Total assets 139,434 126,412
Current liabilities:    
Accounts payable 2,849 15,599
Accrued expenses and other current liabilities 10,252 7,929
Facility financing obligation 75,452 74,582
Deferred sales from collaboration 17,680 17,503
Deferred payments from collaboration 144,431 140,231
Purchase commitment loss - current 20,986 12,475
Warrant liability 18,056  
Total current liabilities 289,706 268,319
Note payable to principal stockholder 49,521 49,521
Sanofi loan facility and profit/loss share obligation 69,978 62,371
Senior convertible notes 27,623 27,613
Non-current purchase commitment loss 52,515 53,692
Other liabilities 16,668 15,225
Total liabilities 506,011 476,741
Commitments and contingencies
Stockholders' deficit:    
Undesignated preferred stock, $0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at June 30, 2016 and December 31, 2015
Common stock, $0.01 par value - 700,000,000 and 550,000,000 shares authorized at June 30, 2016 and December 31, 2015, respectively; 477,741,850 and 428,670,943 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively 4,777 4,287
Additional paid-in capital 2,546,727 2,508,633
Accumulated other comprehensive loss (21) (20)
Accumulated deficit (2,918,060) (2,863,229)
Total stockholders' deficit (366,577) (350,329)
Total $ 139,434 $ 126,412